Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dicerna Pharmaceuticals, Inc.
Lexington, Massachusetts, United Statesdicerna.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Dicerna has multiple programs in clinical development, including nedosiran for primary hyperoxaluria which has completed Phase 3 studies. The company has over 20 active discovery, preclinical, or clinical programs across various therapeutic areas.
- Therapeutic areas
- ImmunologyRare DiseasesGastroenterologyCardiovascularNeurologyInfectious Diseases
- Modalities
- RNA interference (RNAi) therapeutics
- Industry
- Biotech
02
Partnerships
Novo Nordisk A/SF. Hoffmann-La Roche LtdEli Lilly and CompanyAlexion Pharmaceuticals, Inc.Boehringer Ingelheim International GmbHAlnylam Pharmaceuticals, Inc.
Beyond the preview
Go deeper on Dicerna Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dicerna Pharmaceuticals, Inc..